Literature DB >> 17622710

Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied.

Muriel P C Grooteman1, Inge M P M J Wauters, Tom Teerlink, Jos W R Twisk, Menso J Nubé.   

Abstract

BACKGROUND: Asymmetric dimethylarginine (ADMA) levels are increased in hemodialysis (HD) patients. Reports on the effect of various dialysis strategies on ADMA, symmetric dimethylarginine (SDMA) and L-arginine levels are inconclusive. PATIENTS/
METHODS: In this randomized crossover study, 15 patients were dialyzed for 4 weeks with 4 dialyzers, differing in biocompatibility and flux. Dimethylarginine and L-arginine levels were assessed at baseline, and after 4 weeks both before and after HD.
RESULTS: During HD, ADMA and SDMA levels decreased significantly with all dialyzers. Dimethylarginine and L-arginine levels remained stable after 4 weeks of HD with each membrane. After pooling all data, values were mainly explained by variation between time points and patients, not by the type of dialyzer.
CONCLUSION: Despite an intradialytic decrease in dimethylarginines, no changes occurred after 4 weeks of HD with either membrane. Furthermore, the variability of AMDA, SDMA and L-arginine levels was far more dependent on patient-related factors than on the type of dialyzer applied. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622710     DOI: 10.1159/000104868

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

1.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

Review 2.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

Review 3.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 4.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

5.  Symmetric dimethylarginine concentrations in dogs with International Renal Interest Society stage 4 chronic kidney disease undergoing intermittent hemodialysis.

Authors:  André Nanny Vieira Le Sueur; Silvano Salgueiro Geraldes; Alessandra Melchert; Regina Kiomi Takahira; Michael Coyne; Rachel Murphy; Donald Szlosek; Priscylla Tatiana Chalfun Guimarães-Okamoto
Journal:  J Vet Intern Med       Date:  2019-09-12       Impact factor: 3.333

6.  Asymmetric dimethylarginine compartmental behavior during high-flux hemodialysis.

Authors:  Qiuna Du; Jiayuan Gao; Renhua Lu; Yun Jin; Yanfang Zou; Chen Yu; Yucheng Yan
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

7.  Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.

Authors:  Jente Boelaert; Eva Schepers; Griet Glorieux; Sunny Eloot; Raymond Vanholder; Frédéric Lynen
Journal:  Toxins (Basel)       Date:  2016-05-13       Impact factor: 4.546

8.  Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.

Authors:  Jorge L Gamboa; Mias Pretorius; Katie C Sprinkel; Nancy J Brown; T Alp Ikizler
Journal:  BMC Nephrol       Date:  2015-10-22       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.